[Clinical effects of verapamil in the treatment of Peyronie's disease].
Calcium antagonist increase extracellular matrix collagenase activity as well as decrease collagen, fibronectin synthesis and secretion, altering fibroblastic metabolism. Preliminary findings reports that Verapamil improves would healing; Levine (1994) suggest that intralesional calcium antagonist (Verapamil) therapy offers an economical and sensible non operative approach for the treatment of Peyronie's disease. We studied and verified the effect of Verapamil in Peyronie's plaque on 39 men. They received injections of Verapamil bi-weekly in to the plaques for 6 months. Subjectively, improvement in rigidity was observed in 23,1% and a plaque softening observed in 48,7%. Rapid resolution of pain was verified in 90,9%. Objectively, curvature improved in 50% of those in which the diagnosis of Peyronie's disease was less than one year old, but in only 10.2% when disease lasted more than one year. A decreased plaque volume was not observed. There was no toxicity related to Verapamil effect. In this nonrandomized study we retained that Verapamil appears to result in an improvement in patients with symptoms lasting less than one year. For patients without pain with symptoms related to more than one year, Verapamil had no important effect.
Arena
F
F
Divisione di Urologia Azienda Ospedaliera di Parma.
Peracchia
G
G
Di Stefano
C
C
Passari
A
A
Larosa
M
M
Cortellini
P
P
D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010411:Penile Induration / Q000188:drug therapy*; D012189:Retrospective Studies; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D014700:Verapamil